ARS Pharmaceuticals, Inc. (SPRY) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $41.32M | -18.7% |
| 2024 | $50.82M | -28.4% |
| 2023 | $70.97M | -66.3% |
| 2022 | $210.52M | +250.5% |
| 2021 | $60.06M | -84.5% |
| 2020 | $386.57M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $41.32M | -18.7% |
| 2024 | $50.82M | -28.4% |
| 2023 | $70.97M | -66.3% |
| 2022 | $210.52M | +250.5% |
| 2021 | $60.06M | -84.5% |
| 2020 | $386.57M | — |